drugset / Trial / NCT03188159

Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer

NCT03188159 ↗

NaSingle-groupOpen-labelTreatment

Summary

This is a phase II study in patients with recurrent platinum resistant or refractory C5 high-grade serous, endometrioid or undifferentiated ovarian, primary peritoneal or fallopian tube cancer. All patients with high-grade serous, endometrioid or undifferentiated primary peritoneum, fallopian tube or ovarian cancer will be eligible to be screened for this trial and will be required to sign a pre-screening consent form.

Timeline

Start
2017-07-01
Primary completion
2021-07-01
Completion
2022-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Vinorelbine Small molecule 25 mg/m2 Intravenous